Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Catheter Precision (VTAK) EBITDA Margin (2017 - 2025)

Catheter Precision (VTAK) has disclosed EBITDA Margin for 8 consecutive years, with 1336.73% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 164140.0% to 1336.73% in Q3 2025 year-over-year; TTM through Sep 2025 was 1963.42%, a 74059.0% increase, with the full-year FY2024 number at 2676.9%, up 1499708.0% from a year prior.
  • EBITDA Margin was 1336.73% for Q3 2025 at Catheter Precision, up from 2210.38% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 750.5% in Q4 2021 to a low of 171750.0% in Q1 2021.
  • A 5-year average of 38589.96% and a median of 2921.51% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -17118304bps in 2021, then soared 16262917bps in 2023.
  • Catheter Precision's EBITDA Margin stood at 750.5% in 2021, then plummeted by -22645bps to 169200.0% in 2022, then soared by 99bps to 2028.91% in 2023, then decreased by -1bps to 2047.65% in 2024, then soared by 35bps to 1336.73% in 2025.
  • Per Business Quant, the three most recent readings for VTAK's EBITDA Margin are 1336.73% (Q3 2025), 2210.38% (Q2 2025), and 2500.0% (Q1 2025).